Abstract
The anticoagulant effect of heparin during percutaneous (table) were randomised to receive heparin according to either protocol I or II. In this study, the route of heparin administration was randomised so that the drug was given through a sheath in either the femoral vein or in the femoral artery. The anticoagulant effect of heparin was monitored every 15 minutes for 60 minutes. Samples were collected, after aspiration of 6 ml of blood, from both the guiding catheter in the aorta and the sheath in the femoral vein. Both the venous and arterial activated clotting time measurements were assessed simultaneously. A HemoTec (Colorado, USA) machine was used to facilitate simultaneous activated clotting time measurements of two blood samples.
Like the Hemochron machine, the HemoTec blood coagulation timing system also detected in vitro clot formation. One ml blood was collected in cartridges containing the reagent (0-1 ml of kaolin activator) and a plunger. The machine was operated by dropping the plunger through the test sample at programmed intervals. When clotting occurred, the clot retarded the fall of the plunger and this was detected photo-optically. An audible tone signalled the end point.
To assess the variability in activated clotting time measurements, duplicate samples were obtained five minutes apart from 10 It is common practice to give 10 000 units of heparin before percutaneous transluminal coronary angioplasty and a further 5000 units if the procedure extends beyond one hour.2 Heparin administered according to this protocol, however, will leave a significant number of patients inadequately anticoagulated, exposing them to the risk of thrombotic complications. One study has shown that 73% of coronary artery occlusions were related to ineffective anticoagulation.12 . Hollman et al reported that 85% of acute occlusions occurred at the time of diminishing anticoagulation.2 Though both studies refer to acute occlusion after leaving the catheter laboratory, the results show the importance of adequate anticoagulation.
Our results show that to maintain effective anticoagulation during percutaneous transluminal coronary angioplasty, systemic anticoagulation induced by heparin should be monitored. There is controversy about the optimal in vitro test for monitoring heparin treatment. The consensus is that the degree of prolongation of anticoagulation effect gives a better assessment than heparin concentration, because the heparin effect reflects the balance between the direct action of the drug on clotting factors and the ability ofother substances to potentiate or antagonise it. Heparin, in addition to preventing thrombus formation, inhibits platelet to platelet interaction and has also been shown experimentally to suppress the smooth cell proliferation, which contributes to the phenomenon of restenosis. 8 We continued heparin infusion for 24 hours after percutaneous transluminal coronary angioplasty to assess its effect on restenosis.
The results showed no significant reduction in the incidence of restenosis in the patients who were adequately anticoagulated compared with our previous 80 consecutive patients undergoing angioplasty or compared with reported rates of restenosis.
In the subsequent study we found that the activated clotting time values of arterial blood were considerably higher than those of venous blood. We do not think that intermittent flushing of the arterial line with saline containing a very small amount of heparin (approximately 30-40 ml saline containing < 200 units of heparin) explains the difference. The differences may be either related to heparin metabolism or possibly to the anticoagulant effect of the contrast media. Our present knowledge of heparin metabolism is insufficient and further studies are necessary to explain the discrepancy. We recommend activated clotting time monitoring of the arterial blood collected from the guiding catheter because this is more likely to reflect the level of anticoagulation at the site of angioplasty.
Heparin is obtained commercially from porcine intestinal mucosa or bovine lungs. The activities of these two preparations are identical.'9 We used heparin obtained from porcine intestinal mucosa.
We conclude that a bolus of 10 000 units of heparin together with an infusion of 2000 units per hour resulted in adequate anticoagulation in most patients. Activated clotting time should be monitored in all patients to identify those who may be at higher risk of thromboembolic complications because of inadequate anticoagulation. Arterial values of activated clotting time are likely to be higher than venous measurements. A large study is necessary to validate the clinical effectiveness of adequate heparin anticoagulation.
